Gina Collier
Cardiovascular Disease · Sacramento, CANPI 1710218474
Payments from drug & device makers
Across 80 payments — averaging $26.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$930
- AstraZeneca$147
- Cvrx, Inc.$141
- Pfizer$133
- Edwards Lifesciences$85
- Alnylam Pharmaceuticals Inc.$81
- plus $565 from 16 others
What the payments were for
- Food & beverage$1,96294%
- Education$1226%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 32 | $930 |
| AstraZeneca | 4 | $147 |
| Cvrx, Inc. | 10 | $141 |
| Pfizer | 3 | $133 |
| Edwards Lifesciences | 3 | $85 |
| Alnylam Pharmaceuticals Inc. | 3 | $81 |
| E.r. Squibb & Sons, L.L.C. | 3 | $71 |
| Medtronic | 2 | $70 |
| Scpharmaceuticals Inc. | 2 | $56 |
| Amgen | 4 | $52 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $48 |
| Boston Scientific | 1 | $35 |
| Novartis | 2 | $33 |
| Baxter Healthcare | 1 | $29 |
| Actelion Pharmaceuticals US, Inc. | 1 | $27 |
| Kestra Medical Technology Services, Inc. | 1 | $25 |
| Philips North America LLC | 1 | $23 |
| Boehringer Ingelheim | 1 | $22 |
| Merck | 1 | $22 |
| Sanofi-aventis U.S. LLC | 1 | $21 |
| Abiomed | 1 | $17 |
| Novo Nordisk | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MitraClip$125
- CARDIOMEMS$102
How this compares
$2,084 in reported general payments places this provider in the 45th percentile of 2,184 cardiovascular disease providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 84 | $135,441 |
| EliquisApixaban | 100 | $121,888 |
| JardianceEmpagliflozin | 46 | $47,675 |
| FarxigaDapagliflozin Propanediol | 46 | $44,554 |
| XareltoRivaroxaban | 14 | $14,423 |
| ClopidogrelClopidogrel Bisulfate | 186 | $3,049 |
| Metoprolol Succinate | 138 | $1,909 |
| Amiodarone Hcl | 49 | $1,710 |
| Bumetanide | 37 | $1,676 |
| Spironolactone | 93 | $945 |
| Atorvastatin Calcium | 76 | $943 |
| Torsemide | 20 | $782 |
| Potassium Chloride | 34 | $635 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 15 | $472 |
| Losartan Potassium | 46 | $453 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $33 | $135,44184 claims |
| PfizerEliquis | $133 | $121,888100 claims |
| Boehringer IngelheimJardiance | $22 | $47,67546 claims |
| AstraZenecaFarxiga | $147 | $44,55446 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 2,184 cardiovascular disease providers in California.
Other cardiovascular disease in Sacramento
- Jason RogersSacramento$5.1M
- Gagan SinghSacramento$2M
- Jeffrey SouthardSacramento$1.8M
- Thomas SmithSacramento$942K
- Ted LoveHillsborough$102.8M
- Matthew BudoffTorrance$11.3M
- Lori DanielsSan Diego$10.2M
- Paul KurthSanta Barbara$6.1M
- Michael BlumSan Francisco$5.5M
- Tony ChouSan Francisco$5.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.